Peptide vaccines in cancer — old concept revisited

Takumi Kumai, Hiroya Kobayashi, Yasuaki Harabuchi, Esteban Celis

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

Synthetic peptide vaccines aim to elicit and expand tumor-specific T cells capable of controlling or eradicating the tumor. Despite the high expectations based on preclinical studies, the results of clinical trials using peptide vaccines have been disappointing. Thus, many researchers in the field have considered peptide vaccines as outdated and no longer viable for cancer therapy. However, recent progress in understanding the critical roles of immune adjuvants, modes of vaccine administration and T cell dynamics has lead to a rebirth of this approach and reconsidering the use of peptide vaccines for treating malignant disorders.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalCurrent Opinion in Immunology
Volume45
DOIs
StatePublished - Apr 1 2017

Fingerprint

Subunit Vaccines
T-Lymphocytes
Neoplasms
Synthetic Vaccines
Vaccines
Research Personnel
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Peptide vaccines in cancer — old concept revisited. / Kumai, Takumi; Kobayashi, Hiroya; Harabuchi, Yasuaki; Celis, Esteban.

In: Current Opinion in Immunology, Vol. 45, 01.04.2017, p. 1-7.

Research output: Contribution to journalReview article

Kumai, Takumi ; Kobayashi, Hiroya ; Harabuchi, Yasuaki ; Celis, Esteban. / Peptide vaccines in cancer — old concept revisited. In: Current Opinion in Immunology. 2017 ; Vol. 45. pp. 1-7.
@article{503c2137876a4154a539200022e9392c,
title = "Peptide vaccines in cancer — old concept revisited",
abstract = "Synthetic peptide vaccines aim to elicit and expand tumor-specific T cells capable of controlling or eradicating the tumor. Despite the high expectations based on preclinical studies, the results of clinical trials using peptide vaccines have been disappointing. Thus, many researchers in the field have considered peptide vaccines as outdated and no longer viable for cancer therapy. However, recent progress in understanding the critical roles of immune adjuvants, modes of vaccine administration and T cell dynamics has lead to a rebirth of this approach and reconsidering the use of peptide vaccines for treating malignant disorders.",
author = "Takumi Kumai and Hiroya Kobayashi and Yasuaki Harabuchi and Esteban Celis",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.coi.2016.11.001",
language = "English (US)",
volume = "45",
pages = "1--7",
journal = "Current Opinion in Immunology",
issn = "0952-7915",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Peptide vaccines in cancer — old concept revisited

AU - Kumai, Takumi

AU - Kobayashi, Hiroya

AU - Harabuchi, Yasuaki

AU - Celis, Esteban

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Synthetic peptide vaccines aim to elicit and expand tumor-specific T cells capable of controlling or eradicating the tumor. Despite the high expectations based on preclinical studies, the results of clinical trials using peptide vaccines have been disappointing. Thus, many researchers in the field have considered peptide vaccines as outdated and no longer viable for cancer therapy. However, recent progress in understanding the critical roles of immune adjuvants, modes of vaccine administration and T cell dynamics has lead to a rebirth of this approach and reconsidering the use of peptide vaccines for treating malignant disorders.

AB - Synthetic peptide vaccines aim to elicit and expand tumor-specific T cells capable of controlling or eradicating the tumor. Despite the high expectations based on preclinical studies, the results of clinical trials using peptide vaccines have been disappointing. Thus, many researchers in the field have considered peptide vaccines as outdated and no longer viable for cancer therapy. However, recent progress in understanding the critical roles of immune adjuvants, modes of vaccine administration and T cell dynamics has lead to a rebirth of this approach and reconsidering the use of peptide vaccines for treating malignant disorders.

UR - http://www.scopus.com/inward/record.url?scp=85002810614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002810614&partnerID=8YFLogxK

U2 - 10.1016/j.coi.2016.11.001

DO - 10.1016/j.coi.2016.11.001

M3 - Review article

C2 - 27940327

AN - SCOPUS:85002810614

VL - 45

SP - 1

EP - 7

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

SN - 0952-7915

ER -